Sarcomatrix, Inc. is a bio-pharmaceutical company pioneering novel therapeutics that leverage our understanding of muscle biology and tissue regeneration to develop therapies that have potential for broad clinical applicability across multiple disease areas of high unmet need. Our current focus is muscular dystrophy. Muscular dystrophy, a rare disease without a cure, reduces a patient's average life expectancy to 26 years. Our goal is to more than double their life expectancy. Our IP protected vast portfolio of small molecules a7β1 integrin activators and laminin proteins, used as single agents or in combination with cell and gene therapy, may ultimately cure muscular dystrophy.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 450 Sinclair St, Reno,nevada 89501,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.sarcomatrix.com
- Keywords
- Muscular Dystrophy, Rare Disease, muscle wasting, anti aging, Congenital Muscular Dystrophy, small molecules, protein replacement, α7β1 integrin enhancers, sarcopenia, Cachexia, Seed Investment, Angel Investment, Series A Investment, In-License, Out-License.
- HQ
- Reno, Nevada
Sarcomatrix Questions
Sarcomatrix's website is http://www.sarcomatrix.com
Sarcomatrix's LinkedIn profile is https://www.linkedin.com/company/sarcomatrix
Sarcomatrix has
5 employees.
View email and phone details for 5
employees at Sarcomatrix.
Sarcomatrix's industry is
Biotechnology Research
Sarcomatrix's top competitors are
Quercis Pharma,
Waterlily,
Maternal+,
Kadence Bio,
Dog & Whistle,
Automarketer Ai,
Safeflight Corporation,
Owl Therapeutics,
Reno Startup Week,
Brokee.
Sarcomatrix's categories are Biotechnology Research
Sarcomatrix's founding year is 2022
